News & Updates

A dexamethasone-free regimen helps improve control of nausea and vomiting in patients receiving “highly emetogenic” chemotherapy, with the antiemetic effect being superior to that of a dexamethasone-based regimen, according to the results of a phase III trial presented at ASCO Breakthrough 2023.

In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.

At a first screening colonoscopy, older patients are more likely to have a detection of adenomatous polyps and colorectal cancer (CRC), reveals a study.

In patients with previously untreated CD20+ diffuse large B-cell lymphoma (DLBCL), treatment with subcutaneous (SC) rituximab is not inferior to intravenous (IV) rituximab in terms of serum trough levels, efficacy, and tolerability, as shown in a study presented at EHA 2023.

Obesity does not seem to have any significant impact on clinical outcomes, particularly survival, in patients with multiple myeloma (MM), according to a study presented at EHA 2023. However, obese MM patients aged <65 years tend to have a shorter overall survival (OS) than those with normal weight.

Certain comorbidities such as hypertension and diabetes mellitus (DM), along with locally advanced stage at diagnosis and systemic treatment received (ie, doxorubicin), are significantly associated with tumour recurrences among patients with breast cancer, according to a study presented at the recent ASCO Breakthrough 2023.